Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Accuracy of the Enhanced Liver Fibrosis Test in Patients With Type 2 Diabetes Mellitus and Its Clinical Implications.
Arai T, Takahashi H, Seko Y, Toyoda H, Hayashi H, Yamaguchi K, Iwaki M, Yoneda M, Shima T, Fujii H, Morishita A, Kawata K, Tomita K, Kawanaka M, Yoshida Y, Ikegami T, Notsumata K, Oeda S, Atsukawa M, Kamada Y, Sumida Y, Fukushima H, Miyoshi E, Aishima S, Okanoue T, Itoh Y, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Arai T, et al. Among authors: atsukawa m. Clin Gastroenterol Hepatol. 2024 Apr;22(4):789-797.e8. doi: 10.1016/j.cgh.2023.11.022. Epub 2023 Dec 2. Clin Gastroenterol Hepatol. 2024. PMID: 38048934
Factors associated with sustained virological response in 24-week telaprevir-based triple therapy for chronic hepatitis C genotype 1b patients with the IL28B minor genotype.
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Among authors: atsukawa m. Hepatol Res. 2015 Apr;45(4):387-96. doi: 10.1111/hepr.12360. Epub 2014 Jul 18. Hepatol Res. 2015. PMID: 24849518
Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.
Abe H, Tsubota A, Shimada N, Atsukawa M, Kato K, Takaguchi K, Asano T, Chuganji Y, Sakamoto C, Toyoda H, Kumada T, Ide T, Sata M, Aizawa Y. Abe H, et al. Among authors: atsukawa m. Gastroenterol Res Pract. 2014;2014:549709. doi: 10.1155/2014/549709. Epub 2014 Aug 14. Gastroenterol Res Pract. 2014. PMID: 25197269 Free PMC article.
Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
Shoji H, Yoshio S, Mano Y, Kumagai E, Sugiyama M, Korenaga M, Arai T, Itokawa N, Atsukawa M, Aikata H, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Nozaki Y, Kawaguchi T, Torimura T, Abe M, Hiasa Y, Fukai M, Kamiyama T, Taketomi A, Mizokami M, Kanto T. Shoji H, et al. Among authors: atsukawa m. Sci Rep. 2016 Jul 1;6:28814. doi: 10.1038/srep28814. Sci Rep. 2016. PMID: 27363523 Free PMC article.
Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease.
Kumagai E, Mano Y, Yoshio S, Shoji H, Sugiyama M, Korenaga M, Ishida T, Arai T, Itokawa N, Atsukawa M, Hyogo H, Chayama K, Ohashi T, Ito K, Yoneda M, Kawaguchi T, Torimura T, Nozaki Y, Watanabe S, Mizokami M, Kanto T. Kumagai E, et al. Among authors: atsukawa m. Sci Rep. 2016 Oct 14;6:35282. doi: 10.1038/srep35282. Sci Rep. 2016. PMID: 27739482 Free PMC article.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Toyoda H, et al. Among authors: atsukawa m. Hepatology. 2018 Feb;67(2):505-513. doi: 10.1002/hep.29510. Epub 2017 Nov 24. Hepatology. 2018. PMID: 28865152 Free PMC article. Clinical Trial.
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, Atsukawa M, Ido A, Takaki A, Enomoto N, Kato K, Alves K, Burroughs M, Redman R, Pugatch D, Pilot-Matias TJ, Krishnan P, Oberoi RK, Xie W, Chayama K. Kumada H, et al. Among authors: atsukawa m. J Gastroenterol. 2018 Apr;53(4):566-575. doi: 10.1007/s00535-017-1396-0. Epub 2017 Oct 20. J Gastroenterol. 2018. PMID: 29052790 Free PMC article. Clinical Trial.
214 results